Analyst Reports

  • 28 Sep 2023

    Edison Insight: September 2023

    Analyst: Pooya Hemami
    Actinogen Medical Investment Summary and Industry Outlook. Prices at 24 Apr 2023

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 08 Jun 2023

    Edison Investment Research update
    Refining the upcoming XanaMIA Phase 2b study

    Analyst: Pooya Hemami

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 02 May 2023

    Edison Investment Research Quarterly update
    Continued focus on Xanamem

    Analysts: Pooya Hemami 

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 27 Apr 2023

    Edison Insight: April 2023

    Analyst: Pooya Hemami
    Actinogen Medical Investment Summary and Industry Outlook. Prices at 24 Apr 2023

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 30 Mar 2023

    Edison Healthcare Insight: March 2023

    Analyst: Pooya Hemami
    Actinogen Medical Investment Summary and Industry Outlook. Prices at 27 Mar 2023

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 15 Mar 2023

    Edison Investment Research H123 update
    Getting ready for the next Alzheimer’s study

    Analysts: Pooya Hemami 

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 09 Feb 2023

    Edison Healthcare Insight: February 2023

    Analyst: Pooya Hemami
    Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 6 Feb 2023

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 06 Jan 2023

    Edison themes: Outlook for 2023
    Biotechs remain central to novel drug development

    Analyst: Soo Romanoff and Dr Adam McCarter

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 23 Dec 2022

    Edison Investment Research Flash Note
    XanaMIA clears hurdle to start US recruitment

    Analysts: Pooya Hemami and Soo Romanoff

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 09 Dec 2022

    Edison Investment Research Flash Note
    XanaCIDD study in MDD underway

    Analysts: Pooya Hemami and Soo Romanoff

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 08 Dec 2022

    Edison Healthcare Insight: December 2022

    Analyst: Pooya Hemami
    Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 5 Dec 2022

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 10 Nov 2022

    Edison Healthcare Insight: November 2022

    Analyst: Pooya Hemami
    Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 7 Nov 2022

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 31 Oct 2022

    Edison themes: Neuroscience comeback
    Ripe for clinical innovation

    Analysts: Soo Romanoff and Dr Adam McCarter

    Refer to page 5 for Actinogen Medical 

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 19 Oct 2022

    Edison Investment Research Company outlook
    Actinogen – Cognitive enhancer targeting key diseases

    Analysts: Pooya Hemami and Soo Romanoff

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 12 May 2022

    Edison Healthcare Insight: May 2022

    Analyst: Soo Romanoff
    Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 9 May 2022

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 14 Apr 2022

    Edison Healthcare Insight: April 2022

    Analyst: Jonas Peculias
    Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 11 April 2022

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 17 Mar 2022

    Edison Healthcare Insight: March 2022

    Analyst: Jonas Peculias
    Refer to page 5 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 14 March 2022

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 10 Feb 2022

    Edison Healthcare Insight: February 2022

    Analyst: Jonas Peculias
    Refer to page 6 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 7 February 2022

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 09 Dec 2021

    Edison Healthcare Insight: December 2021

    Analyst: Jonas Peculias
    Prices at 6 December 2021

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 12 Nov 2021

    Edison Healthcare Insight: November 2021

    Analyst: Jonas Peculias
    Prices at 9 November 2021

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 14 Oct 2021

    Edison Healthcare Insight: October 2021

    Analyst: Jonas Peculias
    Refer to page 6 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 11 October 2021

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 16 Sep 2021

    Edison Healthcare Insight: September 2021

    Analyst: Jonas Peculias
    Refer to page 6 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 13 September 2021.

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 12 Aug 2021

    Edison Healthcare Insight: August 2021

    Analyst: Jonas Peculias
    Refer to page 6 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 9 August 2021.

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 15 Jul 2021

    Edison Healthcare Insight: July 2021

    Analyst: Jonas Peculias
    Refer to page 6 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 12 July 2021.

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 10 Jun 2021

    Edison Healthcare Insight: June 2021

    Analyst: Jonas Peculias
    Refer to page 6 for Actinogen Medical Investment Summary and Industry Outlook. Prices at 7 June 2021.

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 16 Oct 2019

    Edison Investment Research
    Actinogen Medical: Well-timed XanaHES study saves the day

    Analyst: Jonas Peculias

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 08 May 2019

    Edison Investment Research
    Phase II XanADu trial results

    Analyst: Jonas Peculias

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 18 Mar 2019

    Edison Investment Research
    Differentiated treatment for Alzheimer’s disease

    Analyst: Jonas Peculias

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison. The report solely reflects the views of Edison.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report

Latest results

2023 Full Year Results

View Results Centre

2023 Annual General Meeting

Actinogen’s next Annual General Meeting

Date: November 2023 (TBA)

Read more

Back
to top